HSF2 / Heat shock factor protein 2 · IHC design guide

Design Immunohistochemistry for HSF2

Plan paraffin-section HSF2 IHC using strong spermatogonial staining in testis as a reference (HPA tissue IHC). Assess cytoplasmic and nuclear signal in light of activation-dependent relocation (UniProt), and validate the tissue pattern independently because staining and RNA show low consistency (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for HSF2 (IHC for HSF2): expected localisation Cytoplasmic at rest; nuclear on activation (UniProt), antibody PA1607, validated IHC image, and IHC protocol steps — Printable **HSF2** IHC protocol sheet — expected localisation Cytoplasmic at rest; nuclear on activation (UniProt), antibody PA1607, controls and protocol steps. Open the full HSF2 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

HSF2 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic at rest; nuclear on activation (UniProt)
	Staining pattern	Strong staining in basal spermatogonia; compartment unreported (HPA tissue IHC)
	Antigen retrieval	Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen)
	Positive control ⓘ	Testis
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections (standard IHC practice; not target-specific); target-specific effects are unclear.
	Caveat	Staining and RNA show low consistency; verify independently (HPA tissue IHC)
	Regulation	Activation redistributes HSF2 to nucleus (UniProt)
	Isoform / epitope	2 isoforms; epitope coverage is unknown (UniProt)

Section 1

Recommended HSF2 IHC & IF Protocols

The catalog antibody protocol is accompanied by published HSF2 IHC methods for human colonic mucosa (PMC3923051) and frozen eye sections (PMC4417422).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Tissue sections; selected-image fixative not specified (standard IHC workflow)
Fixation	Image fixative and duration unreported (datasheet PA1607); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% normal serum of the secondary host, 30 min, room temperature (standard)
Primary antibody	Rabbit anti-HSF2, 0.5-1μg/ml (datasheet PA1607)
Primary incubation	Overnight at 4 °C (standard)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	HSF2-positive staining in spermatogonia cells of testis (HPA tissue IHC: High). HPA tissue profile: Selective expression in basal cells of the seminiferous ducts. No signal in the no-primary control.

💡Decision noteFor paraffin sections, start with Tris-EDTA pH 9.0 retrieval at 95–98 °C for 20 min (page retrieval rule).

Section 2

What Is the Expected HSF2 Staining Pattern?

HSF2 can localise to the cytoplasm or nucleus; UniProt describes cytoplasmic localisation during normal growth and movement to the nucleus upon activation (UniProt Q03933). In tissue IHC, HPA reports selective, high staining of spermatogonia at the base of testicular seminiferous ducts (HPA tissue IHC). HPA rates that IHC pattern Approved, while noting low agreement with RNA data and pending external verification (HPA tissue IHC). HSF2 has no transmembrane segment (UniProt Q03933).

What am I looking at on my slide?
Strong staining in spermatogonia at the base of seminiferous ducts.	This matches HPA's selective, high testis IHC pattern (HPA tissue IHC). Score the identified cells and their location within the duct; staining elsewhere in the section does not substitute for that cell-level match.
Predominantly nucleoplasmic staining in identifiable cells.	Nucleoplasmic localisation agrees with HPA ICC-IF images (HPA subcellular). Nuclear localisation is also compatible with activated HSF2 (UniProt Q03933). HPA's tissue IHC summary does not specify a compartment, so compartment alone cannot validate a tissue IHC result.
Staining confined to cell membranes or extracellular material.	That distribution is unexpected for HSF2, which is reported in the cytoplasm and nucleus and has no transmembrane segment (UniProt Q03933). Suspect nonspecific staining or detection artefact, and check whether cellular staining also matches the expected testis pattern.
Broad staining of cell types reported as negative, or diffuse colour across the section.	HPA reports no detection in several named cell types, including adipocytes in adipose tissue and glandular cells in adrenal gland (HPA tissue IHC). Such staining raises concern for cross-reactivity, endogenous detection activity, or background (standard IHC practice); it does not establish HSF2 expression.
No discernible staining in testicular spermatogonia.	This misses the supplied positive tissue benchmark (HPA tissue IHC). First check whether spermatogonia are present and identifiable; then review the IHC detection workflow and controls (standard IHC practice). A negative slide alone cannot distinguish technical failure from a sample-specific result.

💡Expected HSF2 appearanceCall a positive result when identifiable spermatogonia at the base of seminiferous ducts show strong cellular staining (HPA tissue IHC), with nuclear localisation compatible with HPA ICC-IF and UniProt Q03933; membrane-only staining or broad colour in reported negative cell types is suspect (UniProt Q03933; HPA tissue IHC).

How each factor affects the staining
Tissue and cell selection	Testicular spermatogonia provide the clearest supplied positive reference: HPA calls their staining High and describes selective basal-duct expression (HPA tissue IHC). HPA reports no detection in the listed adipose, adrenal, appendix, marrow, breast, bronchus, caudate and cerebellum cell types; these observations are cell-specific, not whole-tissue absence claims (HPA tissue IHC).
Compartment and cell state	UniProt places HSF2 in cytoplasm during normal growth and describes nuclear movement on activation (UniProt Q03933). HPA's ICC-IF summary supports nucleoplasmic localisation (HPA subcellular). Because these sources describe different settings, do not score cytoplasmic staining as artefact solely because an ICC-IF image is nucleoplasmic.
Strength of IHC evidence	The supplied IHC antibodies HPA031455 and CAB016067 are each rated Approved (HPA antibodies). HPA also describes low consistency between antibody staining and RNA expression and says external verification is pending (HPA tissue IHC). Treat the reported cell pattern as a useful benchmark, while recording unexpected results rather than assuming every positive cell is confirmed HSF2.
Protein form and epitope uncertainty	UniProt lists two HSF2 isoforms, no signal peptide or propeptide, and no transmembrane segment (UniProt Q03933). The payload gives no antibody epitope map or isoform coverage (supplied record). Those entries do not predict retrieval conditions, isoform-specific staining, shedding, or a target-specific fixation effect.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Testis section has no signal in identifiable spermatogonia.	The result conflicts with HPA's high spermatogonial IHC staining (HPA tissue IHC); a missing cell population or an unsuccessful IHC run may explain it (standard IHC practice).	Confirm the basal cells are present, inspect the run's positive control, and review retrieval, primary-antibody incubation and detection against the validated workflow (standard IHC practice). Do not infer HSF2 absence from this slide alone.
Many unrelated cell types stain as strongly as spermatogonia.	That breadth conflicts with HPA's selective testis pattern and its listed undetected cell types (HPA tissue IHC). Cross-reactivity or endogenous detection activity is possible (standard IHC practice).	Compare staining with the named cell types in the HPA tissue record; run an appropriate no-primary control and assess detection blocking (standard IHC practice). Report the broad pattern as unconfirmed until cellular specificity is resolved.
Colour is strongest on membranes or outside cells.	HSF2 is reported in cytoplasm and nucleus, with no transmembrane segment (UniProt Q03933). A membrane-only or extracellular pattern is therefore unexpected and may reflect nonspecific deposition (standard IHC practice).	Check a no-primary control and inspect whether the signal follows cell boundaries or tissue debris (standard IHC practice). Base any positive call on identifiable cells and the supplied testis pattern (HPA tissue IHC).
Diffuse colour obscures the nuclei and cell boundaries.	Background from the detection system or inadequate blocking can reduce contrast in chromogenic IHC (standard IHC practice). Diffuse colour cannot establish the selective spermatogonial pattern reported by HPA (HPA tissue IHC).	Examine the no-primary control, review blocking and wash steps, and repeat with conditions from the validated IHC workflow if needed (standard IHC practice). Reassess only where cell identity and localisation remain readable.
A cytoplasmic signal appears alongside nuclear staining.	UniProt describes cytoplasmic HSF2 during normal growth and nuclear movement upon activation (UniProt Q03933); HPA ICC-IF supports a nucleoplasmic location (HPA subcellular). The supplied tissue IHC summary does not settle their relative intensity.	Record the compartments separately and judge whether stained cells match the tissue pattern (HPA tissue IHC). Use control staining to investigate diffuse cytoplasmic colour (standard IHC practice); avoid rejecting a result solely for cytoplasmic signal.
IF/ICC Q: Does nucleoplasmic fluorescence prove the tissue IHC result is correct?	HPA supports nucleoplasmic localisation in ICC-IF, while its tissue IHC evidence reports selective spermatogonial staining and has an Approved rating with stated verification limits (HPA subcellular; HPA tissue IHC).	No. Compare IF/ICC localisation with the HPA subcellular record, and evaluate paraffin-section IHC against its own cell-level tissue pattern and controls (HPA subcellular; HPA tissue IHC; standard IHC practice). Follow the separate IF/ICC guide for that assay.

Source: UniProt Q03933 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing HSF2 staining

PA1607 · IHCAnti-HSF2 antibody, PA1607, IHC(P) IHC(P): Rat Brain Tissue

IF analysis of HSF2 using anti-HSF2 antibody (PA1607). HSF2 was detected in immunocytochemical section of U20S cells. Enzyme antigen retrieval was performed using IHC enzyme antigen retrieval reagent (AR0022) for 15 mins. The cells were blocked with 10% goat serum. And then incubated with 2μg/mL rabbit anti-HSF2 Antibody (PA1607) overnight at 4°C. DyLight®488 Conjugated Goat Anti-Rabbit IgG (BA1127) was used as secondary antibody at 1:100 dilution and incubated for 30 minutes at 37°C. The section was counterstained with DAPI. Visualize using a fluorescence microscope and filter sets appropriate for the label used.

PA1607 · IFIF analysis of HSF2 using anti-HSF2 antibody (PA1607). HSF2 was detected in immunocytochemical section of U20S cells. Enzyme antigen retriev

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000025156-HSF2/tissue/cerebral+cortex#imid_4707328

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000025156-HSF2/tissue/colon#imid_4707246

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000025156-HSF2/tissue/liver#imid_4707247

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000025156-HSF2/tissue/kidney#imid_4707256

HPA · ICC-IF HEK293Human Protein Atlas immunofluorescence, HEK293, antibody HPA031455; green = HSF2, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for HSF2 IHC & IF

🧪Run testis first: spermatogonia should stain (HPA: High in spermatogonia cells). Use adipose tissue adipocytes as the negative comparison (HPA: Not detected in adipocytes); within the testis slide, assess other cells for background without assuming they are HSF2-negative (HPA: only spermatogonia are listed as High).

Positive control tissue: Testis (Spermatogonia cells, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show HSF2 in HEK293, U-251MG, U2OS, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control; a nonimmune immunoglobulin control matched to the primary antibody’s host species and, for a monoclonal antibody, its isotype; and HSF2 knockout material as a biological negative. For chromogenic IHC, block endogenous peroxidase and check the testis control slide for residual background (standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported in the supplied evidence, and the fixative in the PA1607 rat-brain IHC(P) caption is unreported (selected PA1607 IHC(P) caption: fixative not stated). Retrieval dependence is unreported, so assess antigen retrieval on paraffin sections during optimization (standard IHC practice). The supplied evidence does not establish whether frozen sections or IF/ICC are easier, and no testis-specific artefact is reported; ICC-IF images support nucleoplasmic localization in the listed cell lines (HPA: Nucleoplasm, supported).

HPA tissue IHC evidence for HSF2

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Testis	Spermatogonia cells	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Appendix	Glandular cells	Not detected	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →

Section 3

Advanced HSF2 IHC Tips

Troubleshoot HSF2 staining in paraffin sections by checking retrieval, compartment, cell identity, controls, and scoring before interpreting signal.

How should I retrieve HSF2 in paraffin sections when nuclear staining is weak?

Start with Tris-EDTA pH 9.0 heat-induced retrieval at 95–98 °C for 20 min (page retrieval specification: nuclear antigen). Cool sections gradually, then compare staining with a matched section processed through the same detection steps (standard IHC practice). If signal remains weak, test a shorter or longer heating period on adjacent sections while keeping the buffer and detection conditions fixed (standard IHC practice). Check whether improved nuclear signal also raises diffuse background, because HSF2 can occupy both nuclear and cytoplasmic compartments (UniProt Q03933: subcellular location). Record the retrieval condition used for every comparison (standard IHC practice).

Could fixation explain weak or uneven HSF2 staining?

Target-specific fixation sensitivity is unknown: the PA1607 tissue-IHC caption identifies rat brain paraffin sections but does not state a fixative (PA1607 tissue-IHC caption). Record the actual fixative and fixation duration for each specimen before comparing staining intensity across blocks (standard IHC practice). Inspect section edges and centers separately, since uneven processing can produce spatial staining differences (standard IHC practice). Compare adjacent sections with identical retrieval, antibody incubation, and chromogenic detection to isolate the effect of the recorded fixation conditions (standard IHC practice). Do not infer fixation tolerance from HSF2 localisation or its lack of an annotated transmembrane segment (UniProt Q03933: subcellular location and topology).

Should HSF2 stain nuclei, cytoplasm, or both?

Assess nuclear and cytoplasmic staining separately: HSF2 is described as cytoplasmic during normal growth and moving to the nucleus upon activation (UniProt Q03933: subcellular location). Supported nucleoplasmic localisation provides an additional reference for evaluating nuclear signal (HPA: supported nucleoplasm). For chromogenic sections, compare stained nuclei with the counterstain and score cytoplasm in the same cells rather than calling all brown signal nuclear (standard IHC practice). A change in nuclear-to-cytoplasmic distribution is more informative when the compared sections share processing and detection conditions (standard IHC practice). Do not equate nuclear staining alone with demonstrated transcriptional activation; that requires separate functional evidence (UniProt Q03933: function).

How should isoforms and epitope uncertainty affect my staining interpretation?

HSF2 has 2 listed isoforms, so establish which sequence region the IHC-validated antibody recognizes before assigning staining to either isoform (UniProt Q03933: isoforms). The supplied evidence does not identify the antibody epitope or show whether it detects both isoforms (supplied PA1607 caption and UniProt Q03933 record). Compare any documented immunogen region against the isoform sequences and report unresolved coverage explicitly (standard antibody-validation practice). An altered staining pattern cannot by itself establish an isoform switch, especially when retrieval and tissue processing can also change epitope access (standard IHC practice). HSF2 has no annotated transmembrane segment, which supports evaluating intracellular compartments without defining antibody epitope accessibility (UniProt Q03933: topology).

How can IF help verify HSF2 localisation alongside a cell-type marker?

Use an HSF2 channel alongside a marker for the cell population being examined, then assess colocalisation cell by cell (standard IF practice). For testis, spermatogonia offer a documented high-staining population for choosing an appropriate identity marker (HPA: High in testis spermatogonia). Choose fluorophores in channels with low measured tissue autofluorescence and include unstained and single-channel controls before interpreting overlap (standard IF practice). Because HSF2 is intracellular and lacks an annotated transmembrane segment, permeabilise sufficiently to access cytoplasmic and nuclear epitopes, then check that nuclear boundaries remain interpretable (UniProt Q03933: location and topology; standard IF practice). Optimise IF fixation independently of the PA1607 paraffin caption, which reports no fixative (PA1607 tissue-IHC caption).

What should I check when HSF2 chromogenic staining looks diffuse?

First compare the primary-antibody section with a matched no-primary control to identify signal from secondary reagents or the chromogenic detection system (standard IHC practice). Check the peroxidase block and examine whether DAB deposition follows damaged edges, folds, or tissue debris (standard IHC practice). Reduce nonspecific binding through an appropriate blocking step and wash sections consistently before changing the primary-antibody concentration (standard IHC practice). Interpret diffuse cytoplasmic colour cautiously because cytoplasmic HSF2 is biologically plausible during normal growth (UniProt Q03933: subcellular location). Require reproducible cellular boundaries and a convincing compartment pattern before treating diffuse colour as HSF2 signal (standard IHC practice).

How should I quantify HSF2 staining across sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and compartment before scoring; HSF2 can be cytoplasmic or nuclear, so combine neither compartment silently (UniProt Q03933: subcellular location). For each compartment, report the percentage of positive cells and an intensity-based H-score, using the same positivity thresholds across sections (standard IHC quantification practice). If spatial distribution matters, report positive-cell density per mm² of evaluable tissue as a separate measure (standard IHC quantification practice). Normalise cell counts to the number of evaluable cells in the defined population, and exclude folds, necrosis, and section edges consistently (standard IHC quantification practice). Record retrieval and staining batch with each score (standard IHC quantification practice).

How can I distinguish credible HSF2 staining from artefact?

Look for reproducible intracellular staining in identifiable cells, with a separately assessed nuclear component consistent with supported nucleoplasmic localisation (HPA: supported nucleoplasm; standard IHC practice). Testis spermatogonia provide a documented high-staining reference, while the HPA tissue profile carries a low-consistency warning relative to RNA expression (HPA: High in testis spermatogonia; Approved reliability description). Question signal confined to section edges, necrotic areas, or a no-primary control, and investigate residual endogenous peroxidase before calling it positive (standard IHC practice). Cytoplasmic staining is possible during normal growth, but a compartment pattern alone does not prove HSF2 activation (UniProt Q03933: subcellular location and function).

Boster reagents

Best HSF2 / Heat shock factor protein 2 IHC Antibodies

PA1607 has rat brain paraffin-section IHC and U20S-cell IF images; listed reactivity covers human, mouse and rat (PA1607 image captions; catalog reactivity).

Real IHC data Anti-HSF2 antibody, PA1607, IHC(P) IHC(P): Rat Brain Tissue

Anti-Heat shock factor protein 2 HSF2 Antibody ®

Cat # PA1607

View product →

PA1607 is the sole card that will render; it lists IHC, IF and ICC applications with human, mouse and rat reactivity (PA1607 catalog). Its own images show rat brain IHC(P) and IF in U20S cells (PA1607 image captions).

Which to pick: Choose PA1607 for tissue IHC: its own image shows rat brain paraffin-section staining, and the fixative is unreported (PA1607 IHC image caption). Choose PA1607 for image-backed IF/ICC; M04692-1 is a human-reactive rabbit monoclonal listing ICC/IF, but has no IF image in this payload (PA1607 IF image caption; M04692-1 catalog). For cross-species work, PA1607 lists human, mouse and rat reactivity, although its tissue IHC image documents rat only (PA1607 catalog reactivity; PA1607 IHC image caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q03933 (HSF2_HUMAN, Heat shock factor protein 2).
Human Protein Atlas. HSF2 tissue IHC expression (reliability: Approved).
Human Protein Atlas. HSF2 subcellular location (ICC-IF): Localized to the nucleoplasm..
Human Protein Atlas. HSF2 antibody validation summary (2 antibodies).
Heat shock factor 2 levels are associated with the severity of ulcerative colitis. PloS one 2014 — PMC3923051.
Celastrol supports survival of retinal ganglion cells injured by optic nerve crush. Brain research 2015 — PMC4417422.
Integrated Bioinformatics Analysis Identifies Heat Shock Factor 2 as a Prognostic Biomarker Associated With Immune Cell Infiltration in Hepatocellular Carcinoma. Frontiers in genetics 2021 — PMC8669829.
HSF2 drives breast cancer progression by acting as a stage-specific switch between proliferation and invasion. Science advances 2025 — PMC12407055.
PubMed PMID:1871106 — UniProt-cited evidence.
PubMed PMID:14702039 — UniProt-cited evidence.
PubMed PMID:14574404 — UniProt-cited evidence.